logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Sarepta Pharmaceuticals Jumps on Competitor’s Failure

  +Follow August 16, 2013 9:54AM
Share:
Tickers Mentioned:

Sarepta Therapeutics Inc. (SRPT) experienced a bit of schadenfreude on Aug. 16 as a direct competitor stumbled badly at the finish line.

Competitor GlaxoSmithKline plc (GSK) had been neck-and-neck with Serepta in the race to develop a breakthrough muscle disorder drug to treat Duchenne Muscular Dystrophy. Both drugs were far ahead of the pack in the development process.

That is, until Baird analyst Brian Skorney reported that Glaxo’s drug, drisapersen, has encountered major stumbling blocks on several fronts that could significantly hamper development. Skorney cited clinical, regulatory, and commercials issues with the drug. Most importantly, the drug did not seem to effectively treat symptoms of the disease at the targeted dose.

Serepta’s drug, eteplirsen, so far has seemed to be effective at treating symptoms of Duchenne. Clinical trials have taken place in the UK. On Aug. 7 the company released promising clinical trial information, which will form the basis of their application for US FDA approval in early 2014.

Duchenne is a severely debilitating form of muscular dystrophy. The recessive muscular degenerative disorder affects approximately 1 in 3,600 boys, and life expectancy for sufferers is usually around 25. A drug from either company would be the first on the American market designed to treat the disorder.

The London-based GlaxoSmithKline , which is the fourth largest pharmaceutical company in the world, shrugged off the setback. Their stock is up .33 percent to hit $51.70 a share.

Serepta is up 6.77 percent to hit $34.21 a share.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for GSK
fezziwig2008
18 Dec 14 11:17:44
Once Sirikumab works with Enhanze, $GSK will be back for their own Enhanze deal for Arzerra: http://t.co/vnsb04iO9c $HALO
fezziwig2008
18 Dec 14 11:02:23
$GSK may work w Enhanze via $JNJ deal- They're studying Sirikumab for Rheumatoid Arth Subcut- will involve $HALO https://t.co/cMJvmiGwwz
Spiking
18 Dec 14 10:40:31
New $GSK shingles vaccine may challenge $Merck after strong test data http://t.co/czW5zsc2F2
jo whoa
18 Dec 14 10:04:42
RT @MarketCurrents: Agenus up on successful outcome of Glaxo Phase 3 shingles vaccine study http://t.co/vJlNIlRWaG $AGEN $GSK
jo whoa
18 Dec 14 10:04:26
RT @Agenus_Bio: $AGEN entitled to receive royalties on potential commercial sales of HZ/su http://t.co/QK176pODOe #shingles $GSK
jo whoa
18 Dec 14 10:04:10
RT @Agenus_Bio: The results from $GSK's Ph. 3 study containing $AGEN Adjuvant indicates unprecedented #shingles protection http://t.co/QK17…
BoxSxore
18 Dec 14 10:02:14
RT @Agenus_Bio: The results from $GSK's Ph. 3 study containing $AGEN Adjuvant indicates unprecedented #shingles protection http://t.co/QK17…
Agenus
18 Dec 14 10:00:08
The results from $GSK's Ph. 3 study containing $AGEN Adjuvant indicates unprecedented #shingles protection http://t.co/QK176pODOe
LifeSciences BC
18 Dec 14 10:00:00
RT @FiercePharma: GlaxoSmithKline's shingles shot scores in 16,000-patient study http://t.co/N3N4M8QA1c $GSK #pharma #vaccines
Seeking Alpha
18 Dec 14 09:49:49
Complex Sino-U.S. Ties Shine In Avon, Solar And Qualcomm Cases http://t.co/rRmgQHA3v2 $AVP $QCOM $GSK
LifeSciences BC
18 Dec 14 09:45:27
RT @FiercePharma: GlaxoSmithKline CEO: Chin up, investors. Dividend's safe, and Novartis deal awaits http://t.co/GSHUKUO3eB $GSK #pharma by…
The Legacy News
18 Dec 14 09:43:31
GlaxoSmithKline plc Rating Reiterated by BNP Paribas $GSK http://t.co/XcEVNo2dkA
Clair Latin
18 Dec 14 09:41:51
RT @FiercePharma: GlaxoSmithKline's shingles shot scores in 16,000-patient study http://t.co/N3N4M8QA1c $GSK #pharma #vaccines
Jim Johnson, Ph.D.
18 Dec 14 09:37:52
RT @FiercePharma: GlaxoSmithKline's shingles shot scores in 16,000-patient study http://t.co/N3N4M8QA1c $GSK #pharma #vaccines
FiercePharma
18 Dec 14 09:35:08
GlaxoSmithKline's shingles shot scores in 16,000-patient study http://t.co/N3N4M8QA1c $GSK #pharma #vaccines
Sean Breen
18 Dec 14 09:29:48
RT @CarlyHFierce: GlaxoSmithKline CEO: Chin up, investors. Dividend's safe, and Novartis deal awaits: http://t.co/ClK6qlhNy8 $GSK #pharma
Dieter Laevers
18 Dec 14 09:29:18
RT @CarlyHFierce: GlaxoSmithKline CEO: Chin up, investors. Dividend's safe, and Novartis deal awaits: http://t.co/ClK6qlhNy8 $GSK #pharma
Carly Helfand
18 Dec 14 09:29:18
GlaxoSmithKline CEO: Chin up, investors. Dividend's safe, and Novartis deal awaits: http://t.co/ClK6qlhNy8 $GSK #pharma
FiercePharma
18 Dec 14 09:28:52
GlaxoSmithKline CEO: Chin up, investors. Dividend's safe, and Novartis deal awaits http://t.co/GSHUKUO3eB $GSK #pharma by @CarlyHFierce
masmad1
18 Dec 14 08:51:53
RT @MarketCurrents: Agenus up on successful outcome of Glaxo Phase 3 shingles vaccine study http://t.co/vJlNIlRWaG $AGEN $GSK
Peter Green
18 Dec 14 08:45:17
Agenus up on successful outcome of Glaxo Phase 3 shingles vaccine study http://t.co/bkOtAN1wRf $AGEN $GSK $IBB
Agenus
18 Dec 14 08:45:02
$AGEN entitled to receive royalties on potential commercial sales of HZ/su http://t.co/QK176pODOe #shingles $GSK
MarketCurrents
18 Dec 14 08:41:41
Agenus up on successful outcome of Glaxo Phase 3 shingles vaccine study http://t.co/vJlNIlRWaG $AGEN $GSK
Liz Shanahan
18 Dec 14 08:24:56
RT @FiercePharma: Finnish scientists ID link between GSK's swine flu vaccine and narcolepsy http://t.co/xi8BipNCQe $GSK #pharma #vaccines b…
Oliver Staley
18 Dec 14 08:23:58
Glaxo says dividend is secure as analysts question payout, exclusive from moi http://t.co/x8qDrC0CTG via @business $GSK
Market Int Center
18 Dec 14 08:04:34
GlaxoSmithKline PLC $GSK Trading Near $42.59 Resistance Level ( http://t.co/K3CBhPUkym )
Michael Torres, PhD
18 Dec 14 07:54:50
RT @FiercePharma: This week in #Vaccines: $GSK shingles candidate hits PhIII mark; Baxter backs out of vaccines http://t.co/MBG3CXWepE $BAX…
Jeff Taylor
18 Dec 14 07:54:27
RT @CarlyHFierce: $GSK shingles candidate hits its mark in hefty Phase III study: http://t.co/0QBikU7G0y #pharma #vaccines
FiercePharma
18 Dec 14 07:52:46
This week in #Vaccines: $GSK shingles candidate hits PhIII mark; Baxter backs out of vaccines http://t.co/MBG3CXWepE $BAX #pharma
Carly Helfand
18 Dec 14 07:52:46
This week in #Vaccines: $GSK shingles candidate hits PhIII mark; Baxter backs out of vaccines http://t.co/EVImTIygsE $BAX #pharma
BioPharma Dive
18 Dec 14 07:51:28
The 14 drugs most likely to top global #pharma sales in 2015 & 2020 http://t.co/ekssuSJG45 $AZN $JNJ $GSK $ABBV $GILD http://t.co/oqVG5PAFPr
Sy Mukherjee
18 Dec 14 07:51:28
The 14 drugs most likely to top global #pharma sales in 2015 & 2020 http://t.co/7zMh3FAAlv $AZN $JNJ $GSK $ABBV $GILD http://t.co/DkLgNYuq2k
Agenus
18 Dec 14 07:15:59
$AGEN announced a positive outcome of Ph. 3 study of $GSK's #shingles vaccine containing QS-21 Stimulon http://t.co/QK176pODOe
Maleah
18 Dec 14 07:15:11
*Review* How to Make Money in Stocks: http://t.co/CCyhDcgKgS $OIL $TAXI $USO $XOM $EXXI $SFY $GSK $APC $NGG $ERY
Begum Baysan
18 Dec 14 07:08:00
RT @fwpharma: GlaxoSmithKline shareholders back Novartis transaction http://t.co/oNPdgIWwSx $GSK $NVS #pharma
Scott Spencer
18 Dec 14 06:57:57
$AGEN +10% $3.71 partner $GSK reports that Ph3 study for ZOE-50 shingles vaccine meets its primary endpoint...
Jake King
18 Dec 14 06:56:33
RT @PropThinker: $AGEN has faded these data gaps all year. http://t.co/wwW0NafP7Q Tho validating, small royalty potential from these vaccin…
The GMP Group
18 Dec 14 06:52:24
RT @fwpharma: GlaxoSmithKline shareholders back Novartis transaction http://t.co/oNPdgIWwSx $GSK $NVS #pharma
Phil Serafino
18 Dec 14 06:51:22
Glaxo says dividend is secure as analysts question payout http://t.co/xlBkFsje7k via @business $GSK by @ostaley
Dieter Laevers
18 Dec 14 06:50:57
RT @fwpharma: GlaxoSmithKline shareholders back Novartis transaction http://t.co/oNPdgIWwSx $GSK $NVS #pharma
FirstWord Pharma
18 Dec 14 06:50:56
GlaxoSmithKline shareholders back Novartis transaction http://t.co/oNPdgIWwSx $GSK $NVS #pharma
PropThinker
18 Dec 14 06:49:36
$AGEN has faded these data gaps all year. http://t.co/wwW0NafP7Q Tho validating, small royalty potential from these vaccines. $GSK
Vincent
18 Dec 14 06:45:03
"@NoanetTrader: $AGEN great technical setup and "Positive Outcome of Phase 3 Study" with $GSK http://t.co/6eY8TYEwnz"
Seamus
18 Dec 14 06:43:21
RT @CarlyHFierce: $GSK shingles candidate hits its mark in hefty Phase III study: http://t.co/0QBikU7G0y #pharma #vaccines
John Carroll
18 Dec 14 06:41:31
RT @CarlyHFierce: $GSK shingles candidate hits its mark in hefty Phase III study: http://t.co/0QBikU7G0y #pharma #vaccines
Carly Helfand
18 Dec 14 06:41:22
$GSK shingles candidate hits its mark in hefty Phase III study: http://t.co/0QBikU7G0y #pharma #vaccines
The Fly
18 Dec 14 06:21:24
On The Fly: Pre-market Movers $RAD $ORCL $AKS $AGEN $GSK $HTZ $OVAS $TTPH $GOL $WGO $SIMG $DNKN $GNW: Full Story http://t.co/B3tVq4AaO4
Red Acre Investments
18 Dec 14 06:09:30
interesting $GSK reports +ve p3 shingle vacc. $SGYP spinoff $CTRV has a pot'l shingles TX in-licenses HBV/HIV antiviral from $CMRX same day
Matt finston
18 Dec 14 06:08:39
RT @MarketCurrents: China moves ahead with Ebola vaccine trials http://t.co/xOmZHwCmIw #premarket $GSK $MRK
Evnt Trader
18 Dec 14 06:04:15
$GSK Glaxo shingles vaccine candidate successful in Phase 3 study
				
				
  +Follow August 16, 2013 9:54AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.